Activation of a trans-valvular Impella CP pump, but not VA-ECMO, before reperfusion reduced myocardial infarct size and attenuated an increase in TNF-a and IL-6 levels and MMP-9 levels and activity in the LV and renal cortex. The gene discussed is MMP9; the disease is myocardial infarction.